| Description: |
Nedocromil is an inhaled anti-inflammatory agent For the preventive management of asthma.
IC50 Value:
Target: Cysteinyl Leukotriene Receptor(CYSLTR)
in vitro:
in vivo: Nedocromil sodium (10(-4) M) decreased LTB4 releasability and intracellular 5-HETE concentrations in zymosan-stimulated AM from asthmatic patients, and was shown to decrease the LTC4 or LTE4-promoted Formation of LTB4 and 5-HETE . Eight atopic asthmatic subjects inhaled nedocromil or placebo be Fore the AMP challenge. Spirometry and FE(NO) were measured at intervals over a 24-h period. Nedocromil gave partial protection against this decrease in FE(NO). The time-FE(NO) curve (AUC(0-24)) differed significantly between nedocromil and placebo: 2.7% (-3.6 to -9) vs. -6.6% (-12 to -1.3) FE(NO) changes h(-1), P < 0.002, respectively. Nedocromil protected against AMP-induced bronchoconstriction (AMP PC(20)) [nedocromil 182 (72.5-291) mg mL(-1) vs. placebo 21.7 (10.7-33) mg mL(-1), P < 0.002] . Nedocromil sodium relieved symptoms of allergic conjunctivitis and further support a role For nedocromil sodium in the prevention of allergic conjunctivitis . Nedocromil, 2 to 20 mg/kg, significantly (P<0.05) inhibited cell adhesion and emigration, as well as myeloperoxidase release, in wild-type but not Anx-A1(-/-) mice .For the detailed information of Nedocromil, the solubility of Nedocromil in water, the solubility of Nedocromil in DMSO, the solubility of Nedocromil in PBS buffer, the animal experiment (test) of Nedocromil, the cell expriment (test) of Nedocromil, the in vivo, in vitro and clinical trial test of Nedocromil, the EC50, IC50,and Affinity of Nedocromil, Please contact DC Chemicals. |
